Stockreport

Verastem Oncology Provides a Clinical Update for RAMP 203 Trial in Advanced KRAS G12C Mutant Non-Small Cell Lung Cancer [Yahoo! Finance]

Verastem, Inc.  (VSTM) 
Last verastem, inc. earnings: 10/29 04:17 pm Check Earnings Report
US:NASDAQ Investor Relations: verastem.com
PDF and LUMAKRAS™ (sotorasib) plus defactinib in patients previously treated with a G12C inhibitor BOSTON, December 18, 2024 BUSINESS WIRE )--Verastem Oncology (Nasdaq: VS [Read more]